BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37034507)

  • 1. Expression differences between proteins responsible for DNA damage repair according to the Gleason grade as a new heterogeneity marker in prostate cancer.
    Jaworski D; Gzil A; Antosik P; Zarębska I; Dominiak J; Neska-Długosz I; Kasperska A; Grzanka D; Szylberg Ł
    Arch Med Sci; 2023; 19(2):499-506. PubMed ID: 37034507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of DNA mismatch repair proteins in prostate cancer.
    Sharma M; Yang Z; Miyamoto H
    Medicine (Baltimore); 2020 May; 99(19):e20124. PubMed ID: 32384491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
    Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
    Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of TP53BP1 and MLH1 on metastatic capability in cases of locally advanced prostate cancer and their usefulness in clinical practice.
    Gzil A; Jaworski D; Antosik P; Zarębska I; Durślewicz J; Dominiak J; Kasperska A; Neska-Długosz I; Grzanka D; Szylberg Ł
    Urol Oncol; 2020 Jun; 38(6):600.e17-600.e26. PubMed ID: 32280038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer.
    Chen Y; Wang J; Fraig MM; Henderson K; Bissada NK; Watson DK; Schweinfest CW
    Int J Oncol; 2003 May; 22(5):1033-43. PubMed ID: 12684669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status.
    Albero-González R; Hernández-Llodrà S; Juanpere N; Lorenzo M; Lloret A; Segalés L; Duran X; Fumadó L; Cecchini L; Lloreta-Trull J
    Virchows Arch; 2019 Aug; 475(2):223-231. PubMed ID: 31209634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and clinicopathological/molecular characteristics of mismatch repair protein-deficient tumours among surgically treated patients with prostate cancer in a Japanese hospital-based population.
    Kagawa M; Kawakami S; Yamamoto A; Suzuki O; Eguchi H; Okazaki Y; Akagi K; Tamaru JI; Arai T; Yamaguchi T; Ishida H
    Jpn J Clin Oncol; 2021 Apr; 51(4):639-645. PubMed ID: 33244609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
    Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
    [No Abstract]   [Full Text] [Related]  

  • 9. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
    Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
    Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA-PKcs expression predicts response to radiotherapy in prostate cancer.
    Bouchaert P; Guerif S; Debiais C; Irani J; Fromont G
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1179-85. PubMed ID: 22494583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
    Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
    J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defects of DNA mismatch repair in human prostate cancer.
    Chen Y; Wang J; Fraig MM; Metcalf J; Turner WR; Bissada NK; Watson DK; Schweinfest CW
    Cancer Res; 2001 May; 61(10):4112-21. PubMed ID: 11358834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch repair gene expression and genetic instability in testicular germ cell tumor.
    Velasco A; Riquelme E; Schultz M; Wistuba II; Villarroel L; Pizarro J; Berlin A; Ittmann M; Koh MS; Leach FS
    Cancer Biol Ther; 2004 Oct; 3(10):977-82. PubMed ID: 15467433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing how reduced expression levels of the mismatch repair genes MLH1, MSH2, and MSH6 affect repair efficiency.
    Kansikas M; Kasela M; Kantelinen J; Nyström M
    Hum Mutat; 2014 Sep; 35(9):1123-7. PubMed ID: 24924810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma.
    Javeed S; Chughtai A; Zafar G; Khalid F; Batool A; Chughtai AS
    Cureus; 2022 Jul; 14(7):e27448. PubMed ID: 36051725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expressional analysis of MLH1 and MSH2 in breast cancer.
    Malik SS; Masood N; Asif M; Ahmed P; Shah ZU; Khan JS
    Curr Probl Cancer; 2019 Apr; 43(2):97-105. PubMed ID: 30149959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of DNA Mismatch Repair Protein Abnormalities in Sudanese Colorectal Cancer Patients Using Immunohistochemical Methods.
    Zakout YM; Lanza G
    J Gastrointest Cancer; 2019 Sep; 50(3):530-536. PubMed ID: 29850986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
    Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
    Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Msh2 separation of function mutations confer defects in the initiation steps of mismatch repair.
    Kijas AW; Studamire B; Alani E
    J Mol Biol; 2003 Aug; 331(1):123-38. PubMed ID: 12875840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.